We aimed to study for the first time the anti-tumor activity of GP-2250 in BRAF-mutated melanoma cell lines and benign melanocytes, also addressing the expression of parts of the PI3K/AKT/mTOR signaling pathway. This evidence concerns the gene BRAF and neoplasm.